Últimas noticias sobre Elanco Animal Health (NYSE:ELAN) Bolsa

Elanco Animal Health

Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health Inc

ELANIX BIOTECHNOLOGIES AG by ELANIX BIOTECHNOLOGIES AG

WIIM

ALHC

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Shares of health insurance stocks are trading lower in sympathy with UnitedHealth, which reported worse-than-expected Q1 results and cut its FY25 adjusted EPS guidance below estimates on Thursday.

UnitedHealth shares are trading lower after the company on Thursday reported worse-than-expected Q1 results and cut its FY25 adjusted EPS guidance below estimates.

Raymond James analyst Michael Rose maintains Texas Capital Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBI#NASDAQ">TCBI</a>) with a Outperform and lowers the price target from $87 to $80.

News

Price Target

Analyst Ratings

TCBI

Raymond James Maintains Outperform on Texas Capital Bancshares, Lowers Price Target to $80

Wells Fargo analyst Roger Read maintains Diamondback Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) with a Overweight and lowers the price target from $215 to $207.

FANG

Wells Fargo Maintains Overweight on Diamondback Energy, Lowers Price Target to $207

Raymond James analyst David Long reiterates Huntington Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBAN#NASDAQ">HBAN</a>) with a Strong Buy and lowers the price target from $20 to $18.

Reiteration

HBAN

Raymond James Reiterates Strong Buy on Huntington Bancshares, Lowers Price Target to $18

Trading in UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) was quiet Monday. This comes after <a href="https://www.benzinga.com/general/health-care/25/04/44869920/unitedhealth-ceo-says-high-cost-of-us-health-care-simply-not-sustainable">Friday's drop of more </a>than 20%. The company reduced its annual guidance to $26.00 to $26.50 per share. The previous guidance was close to $30.00 per share.
But the selloff may soon end. This is why our team of traders has made UH our Stock of the Day.
&#8220;Buy at former bottoms&#8221; is an old expression on Wall Street. It refers to how, sometimes, when a stock drops to a price level that had previously been support, there is a good chance that it will find support again. There is also a good chance that a rally follows.
You can see on the chart that since January 2022 UnitedHealth has dropped to the $435.00 level seven times. Each time it found support and each time was followed by a move higher.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="594" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21100607/UNH--1024x594.png" alt="" class="wp-image-879873" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21100607/UNH--1024x594.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21100607/UNH--300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21100607/UNH--768x446.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21100607/UNH-.png 1416w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44894251/sp-500-approaching-bubble-territory-us-stocks-remain-historically-overvalued-despite-recent-correction-says-market-researcher">S&amp;P 500 &#8216;Approaching Bubble Territory:&#8217; US Stocks Remain Historically Overvalued Despite Recent Correction, Says Market Researcher</a>
Now the stock is closing in on this important level again.
If a stock is trending lower, it is because there are more shares for sale than there are to be bought. Investors and traders who wish to sell are forced to push the price lower if they want to draw buyers in from the sidelines.
This price action results in a downtrend.
Support is a price level or zone where there is a large amount of buy interest. There are as many, or possibly even more shares to be bought as there are for sale. This is why downtrends pause or end when they reach support.
At times, those who created the support with their buying become concerned that others who wish to buy will be willing to pay a higher price than they are. As a result, they increase their bid prices. Other concerned buyers see this and raise their bid prices as well.
It could result in a bidding war that forces the stock into an uptrend. This may be about to happen once again with UnitedHealth.
Read Next: <a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44895495/wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-delivering-high-dividend-yields-5">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields</a>
Photo: Shutterstock

Technicals

Trading Ideas

Stock Of The Day – Where Will The UnitedHealth Selloff End?

Wells Fargo analyst Roger Read maintains Coterra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) with a Overweight and raises the price target from $35 to $36.

CTRA

Wells Fargo Maintains Overweight on Coterra Energy, Raises Price Target to $36

Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) has acquired an additional 6,556 Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) for approximately $555.8 million, <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44563102/strategy-acquires-22048-more-bitcoin-for-1-92-billion-bringing-total-holdings-to-528185-btc">according to a new SEC filing</a>.
The <a href="https://assets.contentstack.io/v3/assets/bltf8d808d9b8cebd37/blt0d37b0481a7a31df/6805a9fd4851b5fb07d317dd/form-8-k_04-21-2025.pdf">purchase</a> was made between April 14 and April 20, at an average price of $84,785 per Bitcoin including fees.
The move brings MicroStrategy's total Bitcoin holdings to 538,200 BTC, acquired for a combined cost of $36.47 billion at an average price of $67,766 per coin.
The acquisition was funded via proceeds from the company's ongoing at-the-market equity sales programs, raising $547.7 million through its MSTR common stock and $7.8 million through its STRK preferred stock. 
The purchase comes amid renewed institutional interest in Bitcoin, particularly from Japan. 
On Monday, publicly listed Metaplanet (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MTPLF#OTC">MTPLF</a>) added 330 BTC to its treasury, taking its total holdings to 4,855 BTC, currently valued above $420 million.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44894658/deutsche-bank-standard-chartered-reportedly-looking-into-expanding-to-us-crypto-market">Deutsche Bank, Standard Chartered Reportedly Looking Into Expanding To US Crypto Market</a>
This marks the company&#8217;s third Bitcoin purchase in April, reinforcing its position as the tenth-largest public BTC holder.
In a similar move, Japanese fashion company ANAP Holdings revealed it had acquired approximately 16.6591 BTC last week, valued at around $1.4 million. 
The investment will be managed through its subsidiary, ANAP Lightning Capital, and will be revalued quarterly on the company's books. 
ANAP reported a 12.1% Bitcoin yield so far this quarter, with a striking 95% yield in the previous quarter, calculated by its proprietary "BTC Yield" metric.
Despite global macro headwinds, including U.S. equity markets losing $5.4 trillion after Trump's tariff announcement, Bitcoin has remained resilient. 
While the Nasdaq fell 11% in early April, Bitcoin's drawdown was limited to 6%, reinforcing its role as a potential hedge during financial stress.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44894280/how-traders-can-make-money-when-bitcoin-trades-sideways-10x-research">How Traders Can Make Money When Bitcoin Trades Sideways: 10x Research</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

MSTR

MTPLF

Strategy Adds $555 Million In Bitcoin, Ups Stash To 538,200 BTC

Wells Fargo analyst Neil Kalton maintains Emera (TSX:<a class="ticker" href="https://www.benzinga.com/stock/EMA#TSX">EMA</a>) with a Equal-Weight and raises the price target from C$58 to C$61.

TSX:EMA

Wells Fargo Maintains Equal-Weight on Emera, Raises Price Target to C$61

Roadzen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDZN#NASDAQ">RDZN</a>) ("Roadzen" or the "Company"), a global leader in AI-driven mobility and insurance technology, announced today that it has filed a lawsuit in Florida against Meteora Capital Partners, LP ("Meteora") and affiliated entities, alleging willful breach of contract and conduct that has damaged Roadzen and its public market value. The lawsuit is pending in Palm Beach County, Florida, Case Number 50-2025-CA-003675-XXXA-MB.
The lawsuit stems from a Forward Purchase Agreement (FPA) signed in August 2023, under which, as stated in the complaint, Meteora acquired 5 million shares in Roadzen at effectively a zero-cost basis. In exchange, Meteora agreed to remit proceeds from the sale of those shares to Roadzen under specific, clearly defined contractual mechanisms.
Roadzen alleges that, despite negotiated safeguards, Meteora sold over 1.8 million shares without honoring its payment obligations or providing the required notices under the FPA. Roadzen is pursuing a contractual claim of approximately $19.5 million plus additional damages.

Legal

RDZN

Roadzen Sues Meteora Capital Partners For ~$19.5M Over Breach Of Contract, Says Forward Purchase Agreement Involving Zero-Cost Shares, Claiming Unauthorized Sale Of 1.8M Shares Damaged Company And Public Market Value

Benchmark analyst Josh Sullivan maintains Howmet Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>) with a Buy and raises the price target from $85 to $135.

Benchmark Maintains Buy on Howmet Aerospace, Raises Price Target to $135

Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) shares are trading higher Monday after the company reported strong first-quarter results late last week. Multiple analysts raised price targets <a href="https://www.benzinga.com/25/04/44892780/why-netflix-shares-are-trading-higher-here-are-20-stocks-moving-premarket">following the print</a>. 
What Happened: After the market close on Thursday, Netflix reported first-quarter revenue of $10.54 billion, beating analyst estimates of $10.52 billion, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. The streaming giant reported adjusted earnings of $6.61 per share, beating estimates of $5.74 per share.&nbsp;
Markets were closed on Friday, so Monday marks the first trading session following earnings. 
Total revenue was up 13% year-over-year, driven by membership growth and higher pricing. The company said results came in above company expectations due to higher-than-forecasted subscription and ad revenue. 
Netflix guided for 15% revenue growth in the second quarter, citing continued strong trends in memberships and advertising revenue. The company said it expects second-quarter earnings of $7.03 per share, versus estimates of $6.27 per share. 
&#8220;We remain optimistic about our 2025 slate with a lineup that includes returning favorites, series finales, new discoveries and unexpected surprises designed to thrill our members,&#8221; the company said.
Check This Out: <a href="https://www.benzinga.com/general/entertainment/25/04/44877995/netflix-crushes-q1-says-its-working-hard-to-improve-and-expand-its-offering">Netflix Crushes Q1, Says It&#8217;s &#8216;Working Hard To Improve And Expand&#8217; Its Offering</a>
Analyst Changes:
<ul>
<li>Morgan Stanley analyst Benjamin Swinburne maintained Netflix with an Overweight and raised the price target from&nbsp;$1,150&nbsp;to&nbsp;$1,200.</li>
</ul>
<ul>
<li>Canaccord Genuity analyst Maria Ripps maintained Netflix with a Buy and raised the price target from&nbsp;$1,150&nbsp;to&nbsp;$1,200.</li>
</ul>
<ul>
<li>Piper Sandler analyst Matt Farrell maintained Netflix with an Overweight and raised the price target from&nbsp;$1,100&nbsp;to&nbsp;$1,150.</li>
</ul>
<ul>
<li>Rosenblatt analyst Barton Crockett maintained Netflix with a Buy and raised the price target from&nbsp;$1,494&nbsp;to&nbsp;$1,514.</li>
</ul>
<ul>
<li>Needham analyst Laura Martin reiterated Netflix with a Buy and maintained a price target of&nbsp;$1,126.</li>
</ul>
<ul>
<li>JPMorgan analyst Doug Anmuth maintained Netflix with an Overweight and raised the price target from&nbsp;$1,025&nbsp;to&nbsp;$1,150.</li>
</ul>
NFLX Price Action: <a href="http://benzinga.com/quote/nflx">Netflix shares</a> were up 1.64% at $989 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: FP Creative Stock/Shutterstock

Earnings

Movers

NFLX

Investors Are Buying Netflix Stock Following Q1 Earnings: What's Going On?

Raymond James analyst Daniel Tamayo reiterates Farmers National Banc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FMNB#NASDAQ">FMNB</a>) with a Outperform and lowers the price target from $17 to $15.

FMNB

Raymond James Reiterates Outperform on Farmers National Banc, Lowers Price Target to $15

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler cut Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) price target from $182 to $110. Piper Sandler analyst Biren Amin maintained an Overweight rating. Sarepta Therapeutics shares closed at $53.79 on Thursday. See how other analysts view this stock.</li>
<li>Wells Fargo slashed the price target for AutoNation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>) from $194 to $176. Wells Fargo analyst Colin Langan maintained an Equal-Weight rating. AutoNation shares closed at $165.78 on Thursday. See how other analysts view this stock.</li>
<li>Barclays cut Datadog, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) price target from $180 to $125. Barclays analyst Raimo Lenschow maintained an Overweight rating. Datadog shares closed at $91.18 on Thursday. See how other analysts view this stock.</li>
<li>Ascendiant Capital slashed the price target for BioSig Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) from $2.75 to $2.5. Ascendiant Capital analyst Edward Woo maintained a Buy rating. BioSig Technologies shares closed at $0.5644 on Thursday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird cut the price target for Snap-on Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNA#NYSE">SNA</a>) from $349 to $320. Baird analyst Luke Junk maintained a Neutral rating. Snap-on shares closed at $305.44 on Thursday. See how other analysts view this stock.</li>
<li>Rosenblatt increased Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) price target from $1,494 to $1,514. Rosenblatt analyst Barton Crockett maintained a Buy rating. Netflix shares settled at $973.03 on Thursday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan increased The Coca-Cola Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) price target from $74 to $78. JP Morgan analyst Andrea Teixeira maintained an Overweight rating. Coca-Cola shares closed at $73.00 on Thursday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Seaport Global cut Minerals Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTX#NYSE">MTX</a>) price target from $92 to $80. Seaport Global analyst Michael Harrison maintained a Buy rating. Minerals Technologies shares closed at $56.71 on Thursday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler slashed the price target for Westamerica Bancorporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WABC#NASDAQ">WABC</a>) from $54 to $50. Piper Sandler analyst Andrew Liesch maintained a Neutral rating. Westamerica shares settled at $45.97 on Thursday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity slashed Kopin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOPN#NASDAQ">KOPN</a>) price target from $2.5 to $2.25. Canaccord Genuity analyst George Gianarikas maintained a Buy rating. Kopin shares closed at $0.9054 on Thursday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying NFLX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="594" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21100201/image-36-1024x594.png" alt="" class="wp-image-879858" style="width:555px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21100201/image-36-1024x594.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21100201/image-36-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21100201/image-36-768x446.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21100201/image-36.png 1072w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/25/04/44862261/top-3-materials-stocks-that-are-ticking-portfolio-bombs">Top 3 Materials Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

BSGM

DDOG

KOPN

SRPT

WABC

Netflix To Rally More Than 55%? Here Are 10 Top Analyst Forecasts For Monday

Benchmark analyst Josh Sullivan maintains Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) with a Buy and lowers the price target from $250 to $215.

Benchmark Maintains Buy on Boeing, Lowers Price Target to $215

Raymond James analyst David Feaster reiterates Banner (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BANR#NASDAQ">BANR</a>) with a Outperform and lowers the price target from $77 to $65.

BANR

Raymond James Reiterates Outperform on Banner, Lowers Price Target to $65

SAP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) will release its quarterly earnings report on Tuesday, 2025-04-22. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate SAP to report an earnings per share (EPS) of $1.42.
SAP bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $0.02, leading to a 1.11% increase in the share price on the subsequent day.
Here's a look at SAP's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.51</td>
<td>1.33</td>
<td>1.19</td>
<td>1.11</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.49</td>
<td>1.35</td>
<td>1.18</td>
<td>0.88</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>1.0%</td>
<td>7.000000000000001%</td>
<td>6.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745244145_0.png" alt="eps graph" />
<h3>SAP Share Price Analysis</h3>
Shares of SAP were trading at $257.4 as of April 18. Over the last 52-week period, shares are up 33.59%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Insights on SAP</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on SAP.
Analysts have given SAP a total of 5 ratings, with the consensus rating being Outperform. The average one-year price target is $248.8, indicating a potential 3.34% downside.
<h3>Comparing Ratings with Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Salesforce, Palantir Technologies and Intuit, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Salesforce, with an average 1-year price target of $351.74, suggesting a potential 36.65% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Palantir Technologies, with an average 1-year price target of $97.11, suggesting a potential 62.27% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Intuit, with an average 1-year price target of $707.0, suggesting a potential 174.67% upside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
The peer analysis summary offers a detailed examination of key metrics for Salesforce, Palantir Technologies and Intuit, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAP</td>
<td>Outperform</td>
<td>10.73%</td>
<td>$6.94B</td>
<td>3.70%</td>
</tr>
<tr>
<td>Salesforce</td>
<td>Neutral</td>
<td>7.60%</td>
<td>$7.78B</td>
<td>2.85%</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>Neutral</td>
<td>36.03%</td>
<td>$652.99M</td>
<td>1.66%</td>
</tr>
<tr>
<td>Intuit</td>
<td>Outperform</td>
<td>17.04%</td>
<td>$3.03B</td>
<td>2.61%</td>
</tr>
</tbody>
</table>

Key Takeaway:
SAP ranks at the top for Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.
<h3>Delving into SAP's Background</h3>
Founded in Germany in 1972 by former IBM employees, SAP is the world's largest provider of enterprise application software. Known as the leader in enterprise resource planning software, SAP's portfolio also includes software for supply chain management, procurement, travel and expense management, and customer relationship management, among others. The company operates in more than 180 countries and has more than 400,000 customers, approximately 80% of which are small to medium-size enterprises.
<h3>Breaking Down SAP's Financial Performance</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Positive Revenue Trend: Examining SAP's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.73% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: SAP's net margin excels beyond industry benchmarks, reaching 17.07%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): SAP's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 3.7%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): SAP's ROA stands out, surpassing industry averages. With an impressive ROA of 2.23%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.23.
<a href="https://www.benzinga.com/quote/SAP/earnings">To track all earnings releases for SAP visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Peek at SAP's Future Earnings

Baker Hughes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) is preparing to release its quarterly earnings on Tuesday, 2025-04-22. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Baker Hughes to report an earnings per share (EPS) of $0.48.
Anticipation surrounds Baker Hughes's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
The company's EPS beat by $0.07 in the last quarter, leading to a 3.54% increase in the share price on the following day.
Here's a look at Baker Hughes's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.63</td>
<td>0.61</td>
<td>0.49</td>
<td>0.40</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.70</td>
<td>0.67</td>
<td>0.57</td>
<td>0.43</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>3.0%</td>
<td>6.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745244137_0.png" alt="eps graph" />
<h3>Baker Hughes Share Price Analysis</h3>
Shares of Baker Hughes were trading at $38.91 as of April 18. Over the last 52-week period, shares are up 16.27%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Insights on Baker Hughes</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Baker Hughes.
A total of 13 analyst ratings have been received for Baker Hughes, with the consensus rating being Outperform. The average one-year price target stands at $53.38, suggesting a potential 37.19% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Schlumberger, Halliburton and TechnipFMC, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Schlumberger, with an average 1-year price target of $52.88, suggesting a potential 35.9% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Halliburton, with an average 1-year price target of $32.83, suggesting a potential 15.63% downside.</li>
<li>Analysts currently favor an Outperform trajectory for TechnipFMC, with an average 1-year price target of $39.33, suggesting a potential 1.08% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
Within the peer analysis summary, vital metrics for Schlumberger, Halliburton and TechnipFMC are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baker Hughes</td>
<td>Outperform</td>
<td>7.74%</td>
<td>$1.53B</td>
<td>7.13%</td>
</tr>
<tr>
<td>Schlumberger</td>
<td>Outperform</td>
<td>3.27%</td>
<td>$1.96B</td>
<td>5.14%</td>
</tr>
<tr>
<td>Halliburton</td>
<td>Neutral</td>
<td>-2.25%</td>
<td>$1.03B</td>
<td>5.91%</td>
</tr>
<tr>
<td>TechnipFMC</td>
<td>Outperform</td>
<td>13.94%</td>
<td>$387M</td>
<td>7.07%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Baker Hughes ranks highest in revenue growth among its peers. It also leads in gross profit margin. However, it has the lowest return on equity. Overall, Baker Hughes is positioned favorably compared to its peers in terms of revenue growth and gross profit, but lags behind in return on equity.
<h3>All You Need to Know About Baker Hughes</h3>
Following a 2022 reorganization, Baker Hughes operates across two segments: oilfield services and equipment, and industrial and energy technology. The firm's oilfield services and equipment segment, or OFSE, is one of the Big Three oilfield service players, along with SLB and Halliburton, and mostly supplies to hydrocarbon developers and producers, including national oil companies, major integrated firms, and independents. Markets outside of North America buy roughly three quarters of the firm's OFSE. Baker Hughes' industrial and energy technology segment manufactures and sells turbines, compressors, pumps, valves, and related testing and monitoring services across various energy and industrial applications.
<h3>Breaking Down Baker Hughes's Financial Performance</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Positive Revenue Trend: Examining Baker Hughes's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 7.74% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Energy sector.
Net Margin: Baker Hughes's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 16.01%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Baker Hughes's ROE excels beyond industry benchmarks, reaching 7.13%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Baker Hughes's ROA excels beyond industry benchmarks, reaching 3.11%. This signifies efficient management of assets and strong financial health.
Debt Management: Baker Hughes's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.36.
<a href="https://www.benzinga.com/quote/BKR/earnings">To track all earnings releases for Baker Hughes visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What to Expect from Baker Hughes's Earnings

<a href="https://europeancapitalinsights.substack.com/p/eu-vs-china-the-new-great-game-for?r=3nmatg">Central Asia has again </a>emerged as a center of geopolitical rivalry between great powers competing for natural resources and political influence.
Instead of Great Britain and Russia vying for control of trade routes and territory in the 19th century's "Great Game," the European Union (EU) and China are currently courting the region's leaders. Both seek access to the region's vast oil, gas, and mineral wealth.
Central Asia holds massive <a target="_blank" rel="noreferrer noopener" href="https://www.euronews.com/my-europe/2025/04/04/eu-seals-new-central-asia-partnership-deal-as-debut-samarkand-summit-ends">deposits of raw materials</a>. The region has 38.6% of the world's manganese ore, 30% of chromium, 20% of lead, 12.6% of zinc, and 8.7% of titanium.
<a href="https://x.com/eurocapinsights/status/1914255132641861790">As China expands</a> its footprint in the region, the EU seeks to increase its influence in Central Asia. Uzbekistan, Kyrgyzstan, Kazakhstan, Tajikistan, and Turkmenistan are critical for the bloc's energy supplies and green transition.
"Central Asia is becoming a magnet for global powers," Mehmet Fatih Oztarsu, a Senior Researcher at Hankuk University of Foreign Studies in Seoul, <a target="_blank" rel="noreferrer noopener" href="https://cepa.org/article/eu-seeks-to-match-chinese-influence-in-central-asia/">wrote</a> for the Center for European Policy Analysis (CEPA). "The EU aims to strengthen its presence and reduce Chinese influence."
<a href="https://medium.com/@EuropeanCapitalInsights/eu-vs-china-the-new-great-game-for-central-asias-resources-ba1aa564899b">EU officials</a> are courting Central Asian leaders as they try to <a href="https://europeancapitalinsights.substack.com/p/ecb-cuts-rates-amid-trump-tariffs" target="_blank" rel="noreferrer noopener">protect the eurozone</a> from the uncertainty surrounding US trade policy under President Donald Trump. They are concerned that Trump's economic policies could further disrupt global supply chains.
<h2 class="wp-block-heading">China Chips Away At EU's Role in Central Asia</h2>
While the EU is the region's main investor, China is chipping away at that lead. Beijing has<a target="_blank" rel="noreferrer noopener" href="https://www.ituc-csi.org/IMG/pdf/belt_and_road_initiative_in_central_asia.pdf"> invested heavily</a> in the region as part of its Belt and Road Initiative (BRI). It has poured vast sums of funding into infrastructure projects, surveillance systems, and military assistance.
<figure class="wp-block-image"><a href="https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F20074331-748b-486b-a026-6e6138ef998e_1600x903.jpeg" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F20074331-748b-486b-a026-6e6138ef998e_1600x903.jpeg" alt="" /></a><figcaption class="wp-element-caption">Main investors in Central Asia, Source: <a target="_blank" rel="noreferrer noopener" href="https://www.consilium.europa.eu/en/infographics/eu-central-asia-trade/">Council of the European Union</a></figcaption></figure>
China accounts for roughly 22% of <a target="_blank" rel="noreferrer noopener" href="https://foreignaffairs.house.gov/china-snapshot-project-central-asia-2/">Central Asian exports </a>and 37% of their imports. This trade grew to $89 billion in 2023, representing a 27% increase from the previous year. Significantly, China has surpassed Russia as the region's largest trading partner, according to <a target="_blank" rel="noreferrer noopener" href="https://cepa.org/article/china-uses-crises-to-build-central-asia-influence/">CEPA</a>.
Along with closer ties, though, Kyrgyzstan and Tajikistan now owe nearly half of their sovereign debt to China. Public concern about falling into a Chinese debt trap has sparked more than <a target="_blank" rel="noreferrer noopener" href="https://www.orfonline.org/research/amid-russia-ukraine-conflict-advantage-china-in-central-asia">150 protests</a> across the region since 2015.
China's financing aims to expand its geopolitical influence, secure trade routes, and build large-scale infrastructure. In comparison, the EU instead offers loans designed" to accelerate economic transformation, adaptation to a free-market economy, and promotion of human rights," Oztarsu wrote.
<figure class="wp-block-image"><a href="https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4fdee050-db9e-4ba2-ab19-bdf75169d34b_1105x707.png" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4fdee050-db9e-4ba2-ab19-bdf75169d34b_1105x707.png" alt="" /></a><figcaption class="wp-element-caption">Source: <a target="_blank" rel="noreferrer noopener" href="https://foreignaffairs.house.gov/china-snapshot-project-central-asia-2/">US House Foreign Affairs Committee</a></figcaption></figure>
<h2 class="wp-block-heading">Beijing Makes Political Overtures in Central Asia</h2>
Beijing has made political overtures in the region. President Xi Jinping visited Kazakhstan for the fifth time in July last year since assuming power in 2012.
Apart from Russia, this fact marks Kazakhstan as one of the Chinese leader's most frequently visited nations, alongside the US and France. President Xi has visited Russia more frequently, nine times, according to the <a target="_blank" rel="noreferrer noopener" href="https://carnegieendowment.org/posts/2024/07/what-does-xi-jinping-want-from-central-asia?lang=en">Carnegie Endowment for International Peace</a>.
<figure class="wp-block-image is-resized"><a href="https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F61b30952-e9d5-4a06-950a-2cf62b61bfc2_807x720.png" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F61b30952-e9d5-4a06-950a-2cf62b61bfc2_807x720.png" alt="" style="width:920px;height:auto" /></a></figure>
"China's growing attention to Central Asia is perceived as a harbinger of tectonic shifts in regional geopolitics," <a target="_blank" rel="noreferrer noopener" href="https://carnegieendowment.org/people/temur-umarov?lang=en">Temur Umarov</a>, a fellow at the Carnegie Russia Eurasia Center, wrote last year.
China's Central Asian push has not gone unnoticed in Brussels.
<h2 class="wp-block-heading">EU Maneuvers To Offset China's Expansion</h2>
EU representatives and the five former Soviet republics of Central Asia met on <a target="_blank" rel="noreferrer noopener" href="https://www.consilium.europa.eu/en/press/press-releases/2025/04/04/joint-press-release-following-the-first-eu-central-asia-summit/">April 4</a> to strengthen their strategic partnership. The first <a target="_blank" rel="noreferrer noopener" href="https://data.consilium.europa.eu/doc/document/ST-7745-2025-REV-1/en/pdf">EU-Central Asia Summit</a> in Samarkand, Uzbekistan, focused on expanding trade and EU investment.
"After years of successful cooperation it is time to take our partnership with Central Asia to the next level, deepening trade, strengthening regional collaboration and expanding people-to-people ties," António Costa, President of the European Council, said. "The EU remains a reliable forward-looking partner for Central Asia, investing in its long-term sustainable development for mutual, long-lasting benefit."
The delegations discussed the contemporary developments of the Trans-Caspian International Transport Route (TITR). It connects the two regions via Central Asia, the Caspian Sea, the South Caucasus, and Turkey.
Its freight transportation volume increased by <a target="_blank" rel="noreferrer noopener" href="https://caspiannews.com/news-detail/trans-caspian-international-transport-route-sets-new-record-in-2024-2024-12-18-27/">63% to 4.1 million tons</a> in the first 11 months of 2024. The <a target="_blank" rel="noreferrer noopener" href="https://caspiannews.com/news-detail/trans-caspian-international-transport-route-sets-new-record-in-2024-2024-12-18-27/">TITR Coordination Center</a> aims to enhance its competitiveness by reducing the transit time between Europe and China to under 15 days.
Bypassing Russia, the TITR has also become an alternative to China's BRI. The corridor became more critical for China and Europe after Russia invaded Ukraine. The sanctions imposed on Moscow exposed the EU to global supply chain disruptions that drove eurozone inflation to 10.6% in October 2022.
<h2 class="wp-block-heading">EU Boosts Investments In Central Asia</h2>
The European Commission President, Ursula von der Leyen, pledged EU investments of €<a target="_blank" rel="noreferrer noopener" href="https://www.euronews.com/my-europe/2025/04/04/eu-seals-new-central-asia-partnership-deal-as-debut-samarkand-summit-ends">12 billion</a>. The bloc allocated €3 billion for transportation and €2.5 billion for raw materials projects, <a target="_blank" rel="noreferrer noopener" href="https://x.com/vonderleyen/status/1907803357252624762">von der Leyen</a> said.
The EU will also provide €6.4 billion for water, energy, and climate protection. It pledged an additional €<a target="_blank" rel="noreferrer noopener" href="https://www.consilium.europa.eu/en/press/press-releases/2025/04/04/joint-press-release-following-the-first-eu-central-asia-summit/">10 million</a>&nbsp;to enhance Central Asia's connectivity.
"Countries in the region –particularly Kazakhstan and Uzbekistan – have become more significant partners for the EU and its member states," Marcin Popławski, a research fellow for the Centre for Eastern Studies,<a target="_blank" rel="noreferrer noopener" href="https://www.osw.waw.pl/en/publikacje/analyses/2025-04-09/eu-central-asia-summit-samarkand-economy-comes-first"> wrote </a>on April 9. That is "due to increased exports of oil and uranium, a shift facilitated by their cautious stance on the war in Ukraine," Popławski added.
In the first quarter of 2024, Kazakhstan supplied 10.9% of the EU's petroleum oil imports, as reported by <a target="_blank" rel="noreferrer noopener" href="https://ec.europa.eu/eurostat/web/products-eurostat-news/w/ddn-20240701-1">Eurostat</a>. Kazakhstan, the largest economy in the region, supplies 19 of the EU's 34 critical raw materials, according to Eurostat.
<h2 class="wp-block-heading">European Companies Have Presence in Central Asia</h2>
European companies have significant interests in the region. France's TotalEnergies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTE#NYSE">TTE</a>) holds <a target="_blank" rel="noreferrer noopener" href="https://totalenergies.com/kazakhstan">a 16.8% stake</a> in the North Caspian Project consortium to develop the Kashagan oil field.
Dutch Shell plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHEL#NYSE">SHEL</a>) <a target="_blank" rel="noreferrer noopener" href="https://reports.shell.com/investors-handbook/2011/upstream/asia/kazakhstan.html">has a 16.8% stake </a>in the Kashagan oil field, one of the world's largest offshore fields. Shell also holds a 5.4% interest in the Caspian Pipeline Consortium, which exports production from western Kazakhstan to the Black Sea.
To support European corporate interests, the EU has started to focus more heavily on trade. This approach aligns with the expectations of the Central Asian states, according to Popławski.
"The relationship now focuses on targeted cooperation, particularly in areas such as raw materials and transport," Poplawski said. This has expanded "since Russia's full-scale invasion of Ukraine," he added.
Disclaimer:
Any opinions expressed in this article are not to be considered investment advice and are solely those of the authors. European Capital Insights is not responsible for any financial decisions made based on the contents of this article. Readers may use this article for information and educational purposes only.&nbsp;
This article is from an unpaid external contributor. It does not represent Benzinga&#8217;s reporting and has not been edited for content or accuracy.

Asia

Macro Economic Events

Eurozone

Politics

Econ #s

Opinion

ETFs

General

SHEL

EU vs China: The Power Struggle For Central Asia's Resources

Northrop Grumman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-04-22. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Northrop Grumman will report an earnings per share (EPS) of $6.34.
Anticipation surrounds Northrop Grumman's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company beat EPS by $0.04, leading to a 0.81% increase in the share price the following trading session.
Here's a look at Northrop Grumman's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>6.35</td>
<td>6.07</td>
<td>5.93</td>
<td>5.79</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>6.39</td>
<td>7</td>
<td>6.36</td>
<td>6.32</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>-1.0%</td>
<td>2.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745244122_0.png" alt="eps graph" />
<h3>Tracking Northrop Grumman's Stock Performance</h3>
Shares of Northrop Grumman were trading at $540.39 as of April 18. Over the last 52-week period, shares are up 12.5%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Views on Northrop Grumman</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Northrop Grumman.
A total of 10 analyst ratings have been received for Northrop Grumman, with the consensus rating being Outperform. The average one-year price target stands at $572.3, suggesting a potential 5.9% upside.
<h3>Analyzing Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of General Dynamics, Howmet Aerospace and Lockheed Martin, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for General Dynamics, with an average 1-year price target of $293.15, suggesting a potential 45.75% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Howmet Aerospace, with an average 1-year price target of $136.25, suggesting a potential 74.79% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Lockheed Martin, with an average 1-year price target of $508.83, suggesting a potential 5.84% downside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
The peer analysis summary offers a detailed examination of key metrics for General Dynamics, Howmet Aerospace and Lockheed Martin, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Northrop Grumman</td>
<td>Outperform</td>
<td>0.45%</td>
<td>$1.93B</td>
<td>8.42%</td>
</tr>
<tr>
<td>General Dynamics</td>
<td>Neutral</td>
<td>14.31%</td>
<td>$2.08B</td>
<td>5.10%</td>
</tr>
<tr>
<td>Howmet Aerospace</td>
<td>Outperform</td>
<td>9.24%</td>
<td>$602M</td>
<td>7.02%</td>
</tr>
<tr>
<td>Lockheed Martin</td>
<td>Neutral</td>
<td>-1.34%</td>
<td>$690M</td>
<td>7.79%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Northrop Grumman ranks highest in Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.
<h3>All You Need to Know About Northrop Grumman</h3>
Northrop Grumman Corp is a diversified company which is aligned in four operating sectors, which also comprise our reportable segments namely Aeronautics Systems, Defense Systems, Mission Systems and Space Systems. The aerospace segment designs and builds military aircraft, including the F-35, Global Hawk drones, and the B-21 bomber. Defense systems develops artillery, missile systems, and missile defense technologies. Mission systems focuses on radar, navigation, and communication systems, while space systems manufactures satellites, sensors, and rocket motors.
<h3>Key Indicators: Northrop Grumman's Financial Health</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Northrop Grumman's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 0.45%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Northrop Grumman's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 11.83%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 8.42%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Northrop Grumman's ROA stands out, surpassing industry averages. With an impressive ROA of 2.59%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.08, caution is advised due to increased financial risk.
<a href="https://www.benzinga.com/quote/NOC/earnings">To track all earnings releases for Northrop Grumman visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Northrop Grumman's Earnings Outlook

Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Elanco Animal Health Incorporated of Class Action Lawsuit and Upcoming Deadlines – ELAN

Press Releases

Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2024 Financial Results Announcement

Elanco Reinforces Commitment to Veterinary and Pet Owner Education

Elanco Launches Pet Protect™ From the Makers of Advantage®: Veterinarian-Formulated Supplements for Complete Pet Wellness

Elanco to Participate in Upcoming Investor Conferences

Elanco Enters Agreement with Medgene to Commercialize Highly Pathogenic Avian Influenza Vaccine in Dairy Cattle

Elanco Animal Health Reports Fourth Quarter and Full Year 2024 Results

Elanco Announces Changes to Board of Directors; Signs Research Agreement to Explore Novel Therapies for Chronic Kidney Disease and Life Extension in Pets

Elanco Confirms Date and Conference Call for First Quarter 2025 Financial Results Announcement

ELAN

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Elanco Animal Health

Noticias

Últimas noticias sobre Elanco Animal Health (NYSE:ELAN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL